Press "Enter" to skip to content

Pharma stocks could see turbulence from U.S. Senate drug-price hearing

U.S. healthcare stocks could face more turbulence on Tuesday, after a bumpy early 2019, as top executives from some of the largest pharmaceutical companies are expected to get grilled in the U.S. Senate on the high cost of prescription drugs.

Original source: https://health.economictimes.indiatimes.com/news/pharma/pharma-stocks-could-see-turbulence-from-u-s-senate-drug-price-hearing/68168312?utm_source=RSS&utm_medium=ETRSS

Also Read:   Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800